Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma

Neuro-Oncology

Volumn 13, Issue 1, 2011, Pages 119-131

  Essock Burns, Emma ^a,b   Lupo, Janine M ^a   Cha, Soonmee ^a   Polley, Mei Yin ^a   Butowski, Nicholas A ^a   Chang, Susan M ^a   Nelson, Sarah J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antiangiogenic therapy; DSC; Enzastaurin; GBM; MRI; Perfusion imaging

Indexed keywords

ENZASTAURIN; TEMOZOLOMIDE;

ADULT; AGED; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DISEASE FREE SURVIVAL; DRUG RESPONSE; GLIOBLASTOMA; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTOR VARIABLE; TUMOR VASCULARIZATION;

ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DACARBAZINE; DISEASE PROGRESSION; GLIOBLASTOMA; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; INDOLES; MAGNETIC RESONANCE IMAGING; PERFUSION; RADIOTHERAPY, ADJUVANT; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79951606981     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/noq143     Document Type: Article

References (31)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996. (Pubitemid 40349501)
2. Stupp R, Hegi ME, Gilbert MR, Chakravarti A. Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol. 2007;25:4127-4136. (Pubitemid 47492957)
3. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007;11:83-95. (Pubitemid 46075199)
4. Vredenburgh JJ, Desjardins A, Herndon JE, 2nd, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007;13:1253-1259. (Pubitemid 46424067)
5. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27:4733-4740.
6. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med. 2001;7:987-989. (Pubitemid 32937367)
7. Jain RK, Tong RT, Munn LL. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res. 2007;67:2729-2735. (Pubitemid 46548961)
8. Butowski N, Chang SM, Lamborn KR, et al. Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study. Neurooncology. 2010;12:608-613.
9. Teicher BA, Alvarez E, Menon K, et al. Antiangiogenic effects of a protein kinase Cbeta-selective small molecule. Cancer Chemother Pharmacol. 2002;49:69-77.
10. Chen YB, LaCasce AS. Enzastaurin. Expert Opin Investig Drugs. 2008;17:939-944. (Pubitemid 351864330)
11. Tabatabai G, Frank B, Wick A, et al. Synergistic antiglioma activity of radiotherapy and enzastaurin. Ann Neurol. 2007;61:153-161. (Pubitemid 46363842)
12. Robertson MJ, Kahl BS, Vose JM, et al. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2007;25:1741-1746. (Pubitemid 46797955)
13. Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol. 2010;28:1168-1174.
14. Butowski NALK, Chang S,, Hsieh E, et al. Phase II and pharmacogenomics study of enzastaurin plus temozolomide and radiation therapy in patients with glioblastoma multiforme or gliosarcoma. Paper presented at: Proceedings of 2009 American Society of Clinical Oncology Annual Meeting, Abstract No. 2020. San Francisco, CA: University of California-San Francisco; Indianapolis, IN: Eli Lilly. 2009.
15. van den Bent MJ, Vogelbaum MA, Wen PY, Macdonald DR, Chang SM. End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria. J Clin Oncol. 2009;27:2905-2908.
16. Macdonald DR, Cascino TL, Schold SC, Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277-1280. (Pubitemid 20195640)
17. Chang SM, Lamborn KR, Kuhn JG, et al. Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium. Neurooncology. 2008;10:631-642.
18. Wong ET, Brem S. Taming glioblastoma: targeting angiogenesis. J Clin Oncol. 2007;25:4705-4706. (Pubitemid 350086470)
19. Fukumura D, Jain RK. Imaging angiogenesis and the microenvironment. APMIS. 2008;116:695-715.
20. Harrer JU, Hornen S, Oertel MF, Stracke CP, Klotzsch C. Comparison of perfusion harmonic imaging and perfusion MR imaging for the assessment of microvascular characteristics in brain tumors. Ultraschall Med. 2008;29:45-52. (Pubitemid 351294172)
21. Saraswathy S, Crawford FW, Lamborn KR, et al. Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy. J Neurooncol. 2009;91:69-81.
22. Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol. 2003;24:1989-1998. (Pubitemid 37444849)
23. Sorensen AG, Batchelor TT, Zhang WT, et al. A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res. 2009;69:5296-5300.
24. Park I, Chen AP, Zierhut ML, Ozturk-Isik E, Vigneron DB, Nelson SJ. Implementation of 3 T lactate-edited 3D (1) H MR spectroscopic imaging with flyback echo-planar readout for gliomas patients. Ann Biomed Eng. Published online ahead of print July 23, 2010.
25. Nelson SJ, Nalbandian AB, Proctor E, Vigneron DB. Registration of images from sequential MR studies of the brain. J Magn Reson Imaging. 1994;4:877-883.
26. Lupo JM, Cha S, Chang SM, Nelson SJ. Dynamic susceptibilityweighted perfusion imaging of high-grade gliomas: characterization of spatial heterogeneity. AJNR Am J Neuroradiol. 2005;26:1446-1454. (Pubitemid 43733445)
27. Rueckert D, Sonoda LI, Hayes C, Hill DL, Leach MO, Hawkes DJ. Nonrigid registration using free-form deformations: application to breast MR images. IEEE Trans Med Imaging. 1999;18:712-721. (Pubitemid 32262025)
28. Zhang Y, Brady M, Smith S. Segmentation of brain MR images through a hidden Markov random field model and the expectationmaximization algorithm. IEEE Trans Med Imaging. 2001;20:45-57. (Pubitemid 32293419)
29. Saraswathy SCF, Nelson S. J. Semi-automated segmentation of brain tumor lesions in MR images. Paper presented at: Proceedings of the 14th Annual Meeting of International Society of Magnetic Resonance in Medicine, Seatle, WA, Abstract No. 1609. 2006.
30. McKnight TR, von dem Bussche MH, Vigneron DB, et al. Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence. J Neurosurg. 2002;97:794-802. (Pubitemid 35222399)
31. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28:1963-1972.